These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 7806544)

  • 1. Identification of zinc ligands of the insulin-degrading enzyme.
    Perlman RK; Rosner MR
    J Biol Chem; 1994 Dec; 269(52):33140-5. PubMed ID: 7806544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional analysis of conserved residues in the active site of insulin-degrading enzyme.
    Perlman RK; Gehm BD; Kuo WL; Rosner MR
    J Biol Chem; 1993 Oct; 268(29):21538-44. PubMed ID: 8104941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in a zinc-binding domain of human insulin-degrading enzyme eliminate catalytic activity but not insulin binding.
    Gehm BD; Kuo WL; Perlman RK; Rosner MR
    J Biol Chem; 1993 Apr; 268(11):7943-8. PubMed ID: 8463315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of glutamate-169 as the third zinc-binding residue in proteinase III, a member of the family of insulin-degrading enzymes.
    Becker AB; Roth RA
    Biochem J; 1993 May; 292 ( Pt 1)(Pt 1):137-42. PubMed ID: 8099278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Yeast as a tractable genetic system for functional studies of the insulin-degrading enzyme.
    Kim S; Lapham AN; Freedman CG; Reed TL; Schmidt WK
    J Biol Chem; 2005 Jul; 280(30):27481-90. PubMed ID: 15944156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-degrading enzyme.
    Authier F; Posner BI; Bergeron JJ
    Clin Invest Med; 1996 Jun; 19(3):149-60. PubMed ID: 8724818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An unusual active site identified in a family of zinc metalloendopeptidases.
    Becker AB; Roth RA
    Proc Natl Acad Sci U S A; 1992 May; 89(9):3835-9. PubMed ID: 1570301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Determinants of Substrate Specificity in Human Insulin-Degrading Enzyme.
    Stefanidis L; Fusco ND; Cooper SE; Smith-Carpenter JE; Alper BJ
    Biochemistry; 2018 Aug; 57(32):4903-4914. PubMed ID: 30004674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular bases for the recognition of short peptide substrates and cysteine-directed modifications of human insulin-degrading enzyme.
    Malito E; Ralat LA; Manolopoulou M; Tsay JL; Wadlington NL; Tang WJ
    Biochemistry; 2008 Dec; 47(48):12822-34. PubMed ID: 18986166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation of active site residues of insulin-degrading enzyme alters allosteric interactions.
    Song ES; Daily A; Fried MG; Juliano MA; Juliano L; Hersh LB
    J Biol Chem; 2005 May; 280(18):17701-6. PubMed ID: 15749695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure based discovery of small molecules to regulate the activity of human insulin degrading enzyme.
    Çakir B; Dağliyan O; Dağyildiz E; Bariş İ; Kavakli IH; Kizilel S; Türkay M
    PLoS One; 2012; 7(2):e31787. PubMed ID: 22355395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of glutamate residues essential for catalytic activity and zinc coordination in aminopeptidase A.
    Vazeux G; Wang J; Corvol P; Llorens-Cortès C
    J Biol Chem; 1996 Apr; 271(15):9069-74. PubMed ID: 8621556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formation of insulin fragments by insulin-degrading enzyme: the role of zinc(II) and cystine bridges.
    Bellia F; Pietropaolo A; Grasso G
    J Mass Spectrom; 2013 Feb; 48(2):135-40. PubMed ID: 23378084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of copper(II) and zinc(II) in the degradation of human and murine IAPP by insulin-degrading enzyme.
    Bellia F; Grasso G
    J Mass Spectrom; 2014 Apr; 49(4):274-9. PubMed ID: 24719342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro degradation of insulin-like peptide 3 by insulin-degrading enzyme.
    Zhang WJ; Luo X; Guo ZY
    Protein J; 2010 Feb; 29(2):93-8. PubMed ID: 20082125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The C-terminal domain of human insulin degrading enzyme is required for dimerization and substrate recognition.
    Li P; Kuo WL; Yousef M; Rosner MR; Tang WJ
    Biochem Biophys Res Commun; 2006 May; 343(4):1032-7. PubMed ID: 16574064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism.
    Shen Y; Joachimiak A; Rosner MR; Tang WJ
    Nature; 2006 Oct; 443(7113):870-4. PubMed ID: 17051221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatostatin: a novel substrate and a modulator of insulin-degrading enzyme activity.
    Ciaccio C; Tundo GR; Grasso G; Spoto G; Marasco D; Ruvo M; Gioia M; Rizzarelli E; Coletta M
    J Mol Biol; 2009 Feb; 385(5):1556-67. PubMed ID: 19073193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Han ethnicity-specific type 2 diabetic treatment from traditional Chinese medicine?
    Chen KC; Chang SS; Tsai FJ; Chen CY
    J Biomol Struct Dyn; 2013; 31(11):1219-35. PubMed ID: 23146021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of indole-based activators of insulin degrading enzyme.
    Kraupner N; Dinh CP; Wen X; Landry V; Herledan A; Leroux F; Bosc D; Charton J; Maillard C; Warenghem S; Duplan I; Piveteau C; Hennuyer N; Staels B; Deprez B; Deprez-Poulain R
    Eur J Med Chem; 2022 Jan; 228():113982. PubMed ID: 34815130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.